Kathleen Knights

2.8k total citations
55 papers, 2.2k citations indexed

About

Kathleen Knights is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Kathleen Knights has authored 55 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pharmacology, 19 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Kathleen Knights's work include Pharmacogenetics and Drug Metabolism (32 papers), Drug Transport and Resistance Mechanisms (15 papers) and Eicosanoids and Hypertension Pharmacology (15 papers). Kathleen Knights is often cited by papers focused on Pharmacogenetics and Drug Metabolism (32 papers), Drug Transport and Resistance Mechanisms (15 papers) and Eicosanoids and Hypertension Pharmacology (15 papers). Kathleen Knights collaborates with scholars based in Australia, United Kingdom and Thailand. Kathleen Knights's co-authors include John O. Miners, Peter I. Mackenzie, Andrew Rowland, David J. Elliot, Benedetta C. Sallustio, Kushari Bowalgaha, Arduino A. Mangoni, J. Brian Houston, Matthew J. Sykes and Peter J. Meffin and has published in prestigious journals such as Analytical Biochemistry, Journal of Pharmacology and Experimental Therapeutics and Archives of Biochemistry and Biophysics.

In The Last Decade

Kathleen Knights

55 papers receiving 2.1k citations

Peers

Countries citing papers authored by Kathleen Knights

Since Specialization

Citations

This map shows the geographic impact of Kathleen Knights's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Knights with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Knights more than expected).

Fields of papers citing papers by Kathleen Knights

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Knights. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Knights. The network helps show where Kathleen Knights may publish in the future.

Co-authorship network of co-authors of Kathleen Knights

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Knights. A scholar is included among the top collaborators of Kathleen Knights based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Knights. Kathleen Knights is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia 2017 ·Biochemical Pharmacology ·John O. Miners, Nuy Chau, Andrew Rowland, (unknown), Ross A. McKinnon, Peter I. Mackenzie, Geoffrey T. Tucker, Kathleen Knights, Ganessan Kichenadasse	71
2	Farmaci antinfiammatori non steroidei e rischio di ictus nell’età avanzata: controversie e opportunità 2011 ·Giornale italiano di cardiologia ·Arduino A. Mangoni, Kathleen Knights	2
3	Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation 2011 ·Drug Metabolism and Disposition ·John O. Miners, Kushari Bowalgaha, David J. Elliot, Paweł Baranczewski, Kathleen Knights	94
4	Use of non‐steroidal anti‐inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community 2010 ·Pharmacoepidemiology and Drug Safety ·Arduino A. Mangoni, Richard Woodman, Andrew L. Gilbert, Kathleen Knights	13
5	Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity 2010 ·Expert Review of Clinical Pharmacology ·Kathleen Knights, Arduino A. Mangoni, John O. Miners	87
6	Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators 2010 ·Drug Metabolism Reviews ·Kathleen Knights, John O. Miners	30
7	Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters 2009 ·Drug Metabolism and Disposition ·Andrew Rowland, Kathleen Knights, Peter I. Mackenzie, John O. Miners	30
8	Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP‐glucuronosyltransferases: Inhibition by NSAIDs 2009 ·British Journal of Clinical Pharmacology ·Kathleen Knights, Leanne K. Winner, David J. Elliot, Kushari Bowalgaha, John O. Miners	55
9	Human Renal Cortical and Medullary UDP-Glucuronosyltransferases (UGTs): Immunohistochemical Localization of UGT2B7 and UGT1A Enzymes and Kinetic Characterization of S-Naproxen Glucuronidation 2007 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), John O. Miners, James S. Brennan, Anthony J. Thomas, Kathleen Knights	32
10	Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Andrew Rowland, (unknown), David J. Elliot, Peter I. Mackenzie, Kathleen Knights, John O. Miners	133
11	S‐Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP‐glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen 2005 ·British Journal of Clinical Pharmacology ·Kushari Bowalgaha, David J. Elliot, Peter I. Mackenzie, Kathleen Knights, Stellan Swedmark, John O. Miners	89
12	Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7 2003 ·Biochemical Pharmacology ·(unknown), John O. Miners, Alan M. F. Stapleton, Anthony J. Thomas, Benedetta C. Sallustio, Kathleen Knights	74
13	Nafenopin–, Ciprofibroyl–, and Palmitoyl–CoA Conjugation in Vitro: Kinetic and Molecular Characterization of Marmoset Liver Microsomes and Expressed MLCL1 2001 ·Archives of Biochemistry and Biophysics ·Chris Drogemuller, (unknown), Kathleen Knights	3
14	In Vitro Covalent Binding of Nafenopin–CoA to Human Liver Proteins 2000 ·Toxicology and Applied Pharmacology ·Benedetta C. Sallustio, (unknown), Chris Drogemuller, Kathleen Knights	33
15	ROLE OF HEPATIC FATTY ACID:COENZYME A LIGASES IN THE METABOLISM OF XENOBIOTIC CARBOXYLIC ACIDS 1998 ·Clinical and Experimental Pharmacology and Physiology ·Kathleen Knights	46
16	Kinetic characteristics of rat liver peroxisomal nafenopin-CoA ligase 1995 ·Biochemical Pharmacology ·(unknown), John K. MacLeod, Inderjit Singh, Kathleen Knights	13
17	Inhibition of rat peroxisomal palmitoyl-CoA ligase by xenobiotic carboxylic acids 1992 ·Biochemical Pharmacology ·(unknown), Kathleen Knights	19
18	Inhibition kinetics of hepatic microsomal long chain fatty acid-CoA ligase by 2-arylpropionic acid non-steroidal anti-inflammatory drugs 1992 ·Biochemical Pharmacology ·Kathleen Knights, (unknown)	30
19	Enhanced chiral inversion of R-ibuprofen in liver from rats treated with clofibric acid 1991 ·Biochemical Pharmacology ·Kathleen Knights, (unknown), (unknown)	20
20	A radioisotopic assay of picomolar concentrations of coenzyme A in liver tissue 1988 ·Analytical Biochemistry ·Kathleen Knights, Roger Drew	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact